StoxSai Life Sciences vs Dr. Lal Path Labs: share price & financials comparison
NSE: SAILIFE vs LALPATHLAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sai Life Sciences vs Dr. Lal Path Labs at a glance
Sai Life Sciences (SAILIFE) has a market capitalisation of ₹40,972 Cr, against ₹33,443 Cr for Dr. Lal Path Labs (LALPATHLAB). Over the past year Sai Life Sciences has returned +108.9%, compared with +26.4% for Dr. Lal Path Labs. On valuation, Dr. Lal Path Labs trades at a lower P/E of 57.3 versus 202.3. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 7.5%). Sai Life Sciences comes out ahead on growth, momentum and technicals. Dr. Lal Path Labs comes out ahead on size, valuation and profitability. Across the scored metrics below, Sai Life Sciences leads on 6 and Dr. Lal Path Labs on 5. On StoxGud's 10-point checklist, Sai Life Sciences scores 6/10 and Dr. Lal Path Labs scores 9/10.
| Metric | Sai Life Sciences | Dr. Lal Path Labs |
|---|---|---|
| Size | ||
| Market cap | ₹40,972 Cr | ₹33,443 Cr |
| Revenue (latest FY) | ₹2,192 Cr | ₹2,763 Cr |
| Net profit (latest FY) | ₹349 Cr | ₹505 Cr |
| Valuation | ||
| P/E | 202.3 | 57.3 |
| P/B | 15.24 | 12.19 |
| Dividend yield | — | 0.67% |
| Profitability | ||
| Return on equity | 7.5% | 21.3% |
| Net profit margin | 8.5% | 19.2% |
| Operating margin | 29.5% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +22.5% | +19.6% |
| Net profit growth (YoY) | — | +27.6% |
| Revenue CAGR (multi-year) | — | +11.8% |
| Financial health | ||
| Debt to equity | 0.17 | 0.00 |
| Momentum | ||
| 1-month return | +31.9% | +4.3% |
| 1-year return | +108.9% | +26.4% |
| 3-year CAGR | — | +15.0% |
| 5-year CAGR | — | +1.7% |
| 10-year CAGR | — | +13.7% |
| Distance from 52W high | +0.0% | -1.8% |
| Technicals | ||
| RSI (14) | 93 | 68 |
| Price vs 200-day avg | +56.3% | +19.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sai Life Sciences | Dr. Lal Path Labs |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sai Life Sciences or Dr. Lal Path Labs?
Sai Life Sciences has a market cap of ₹40,972 Cr and Dr. Lal Path Labs has a market cap of ₹33,443 Cr as of 13 Nov 2026.
Which has a lower P/E, Sai Life Sciences or Dr. Lal Path Labs?
Dr. Lal Path Labs has the lower P/E: Sai Life Sciences trades at 202.3 and Dr. Lal Path Labs at 57.3.
Which gave better returns in the last year, Sai Life Sciences or Dr. Lal Path Labs?
Sai Life Sciences did better: Sai Life Sciences returned +108.9% and Dr. Lal Path Labs returned +26.4% over one year.
What is the difference between Sai Life Sciences and Dr. Lal Path Labs?
Both are NSE-listed companies in Healthcare. Sai Life Sciences is about 1.2 times the size of Dr. Lal Path Labs by market cap. In the latest financial year Sai Life Sciences reported revenue of ₹2,192 Cr and Dr. Lal Path Labs ₹2,763 Cr. Operating margin is 29.5% for Sai Life Sciences and 29.5% for Dr. Lal Path Labs. Debt to equity is 0.17 for Sai Life Sciences and 0.00 for Dr. Lal Path Labs.
Which is better, Sai Life Sciences or Dr. Lal Path Labs?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Sai Life Sciences leads on 6 and Dr. Lal Path Labs on 5. Sai Life Sciences is ahead on growth, momentum and technicals. Dr. Lal Path Labs is ahead on size, valuation and profitability. On StoxGud's rules-based checklist Sai Life Sciences scores 6/10 and Dr. Lal Path Labs scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.